{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:57:43Z","timestamp":1790859463302,"version":"4.1.0"},"reference-count":0,"publisher":"The Journal of Rheumatology","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study evaluated the comparative safety of Janus kinase inhibitors (JAKi) vs tumor necrosis factor inhibitors (TNFi) among older adults aged \u226565 years with rheumatoid arthritis (RA), including a prespecified subgroup of patients aged \u226575 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using the TriNetX U.S. Collaborative Network. Adults aged \u226565 years with RA who initiated JAKi or TNFi between 2016 and 2023 were included. Propensity score matching (1:1) was used to balance demographics, comorbidities, medications, and healthcare utilization. Patients were followed for up to 3 years. Primary outcomes were venous thromboembolism (VTE) and major adverse cardiovascular events (MACE). Secondary outcomes included malignancy and all-cause mortality. Cox proportional hazards models estimated hazard ratios (HRs) with 95% confidence intervals (CIs). Sensitivity analyses using an as-treated (AT) design and a prespecified subgroup analysis of adults aged \u226575 years were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, 1,304 patients remained in each group. Over 3 years, JAKi vs TNFi was not associated with increased risk of VTE (50 vs 43 events; HR 1.18, 95% CI 0.79-1.78), MACE (164 vs 148; HR 1.13, 95% CI 0.91-1.41), malignancy (63 vs 68; HR 0.94, 95% CI 0.66-1.32), or mortality (71 vs 66; HR 1.10, 95% CI 0.79-1.54). Findings were consistent in the \u226575-year subgroup and as-treated analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort of older adults with RA, initiation of JAK inhibitors was not associated with higher risks of MACE, VTE, malignancy, or mortality compared with TNF inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.2026-0333","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:15:18Z","timestamp":1790856918000},"page":"jrheum.2026-0333","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Safety of JAK versus TNF Inhibitors in Older Adults with Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study"],"prefix":"10.3899","author":[{"given":"Betul","family":"Ibis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furkan","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Sheehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devyani","family":"Misra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2026,10,1]]},"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.2026-0333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:15:19Z","timestamp":1790856919000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.2026-0333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":0,"alternative-id":["10.3899\/jrheum.2026-0333"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.2026-0333","relation":{},"ISSN":["0315-162X","1499-2752","0315-162X"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"},{"value":"0315-162X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}